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Uncontrolled cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplantation
causes signiﬁcant morbidity and mortality. Adoptive transfer of CMV-speciﬁc cytotoxic T lymphocytes (CTLs)
is a promising therapy to treat reactivation and prevent viral disease. In this article, we describe the gener-
ation of clinical-grade CMV-speciﬁc CTLs directly from granulocyte colony-stimulating factoremobilized
hemopoietic progenitor cell (G-HPC) products collected for transplantation. This method requires less than
2.5% of a typical G-HPC product to reproducibly expand CMV-speciﬁc CTLs ex vivo. Comparison of 11 CMV CTL
lines generated from G-HPC products with 52 CMV CTL lines generated from nonmobilized peripheral blood
revealed similar expansion kinetics and phenotype. G-HPCederived CTLs produced IFN-g after reexposure
to CMVpp65 antigen and exhibited CMV-directed cytotoxicity but no alloreactivity against transplantation
recipientederived cells. Seven patients received CMV-speciﬁc CTL lines expanded from G-HPC products in a
prophylactic adoptive immunotherapy phase I/II clinical trial. Use of G-HPC products will facilitate integration
of CTL generation into established quality systems of transplantation centers and more rapid inclusion of
T cell therapies into routine clinical care.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Human cytomegalovirus (CMV) is a herpesvirus that
infects more than 50% of the population [1]. Primary infec-
tion is generally self-limiting, but results in the establish-
ment of a life-long latent infection subsequently controlled
by a robust innate and adaptive cell-mediated immune
response [2-6]. CMV reactivation occurs frequently after
hematopoietic stem cell transplantation (HSCT), and if
uncontrolled, can cause signiﬁcant morbidity and mortality.
Clinical complications include myelosuppression, encepha-
litis, retinitis, colitis, and pneumonia [5,7-9]. To prevent
CMV-related disease, transplantation centers continually
monitor viral load to guide the use of preemptive antiviral
therapy [10]. Ganciclovir and foscarnet are effective but can
cause side effects, includingmyelosuppression, renal toxicity,
and increased risk of bacterial and fungal infections [11,12].
Additional concerns are the emergence of antiviral-resistant
strains and onset of late CMV disease [13,14].dgments on page 733.
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13.01.021The inability of HSCT recipients to adequately control viral
replication is related to deﬁcits in cell-mediated immunity,
particularly the delayed reconstitution of CMV-speciﬁc CD8þ
and CD4þ T cells after transplantation [15,16]. Several
previous investigators have conducted clinical trials with the
aim of rapidly restoring CMV immunity in allogeneic HSCT
recipients through the adoptive transfer of CMV-speciﬁc
cytotoxic T lymphocytes (CTLs) isolated and expanded
ex vivo from the blood of healthy donors [17-27]. Initial
studies established the feasibility of this approach by
infusing CMV-speciﬁc T cell clones into patients after HSCT
[20]. CMV immunity improved after infusion in a dose-
dependent manner, and TCR rearrangements consistent
with the infused CTLs could be detected for up to 12 weeks
by PCR [20]. Manufacturing the CTL products proved tech-
nically difﬁcult and labor-intensive, however, requiring
cloning by limiting dilution. Subsequent studies consistently
demonstrated the safety of infusing allogeneic CMV-speciﬁc
T cells with promising clinical outcomes, although direct
comparison of these studies is difﬁcult, considering the
signiﬁcant variability in the composition of T cell products,
CMV epitopes targeted, method of manufacture, time of
infusion, cell dose, and risk of CMV disease. Ultimately, the
inclusion of adoptive immunotherapy into routine clinical
care will require efﬁcient methods for CTL generation andTransplantation.
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transplantation programs.
To date, clinical trials using ex vivo-expanded virus-
speciﬁc T cells, including trials conducted at our own
center, have used blood collected from donors before starting
granulocyte colony-stimulating factor (G-CSF) to mobilize
hemopoietic progenitor cells (HPCs). Our institutional
experience has been that obtaining blood products from
donors before transplantation is often difﬁcult for a range of
regulatory, logistic, and geographic reasons. Furthermore,
patients with unrelated donors collected overseas have been
ineligible for immunotherapy owing to the complexities
of obtaining and transporting the separate blood donation
before mobilization. A solution to this problem is to expand
virus-speciﬁc T cells directly from G-CSFemobilized HPC
(G-HPC) apheresis products using cells in excess of the
amount required for transplantation. This would have the
additional beneﬁt of using well-established transplantation
center procedures for donor assessment, infectious disease
testing, product collection, labeling, and transport to the
processing facility.
Despite the higher T cell content of G-HPC products
compared with bone marrow, initial clinical studies revealed
no increased risk of acute graft-versus-host disease (GVHD)
after allogeneic HSCT [28-32]. More recently, transplantation
with G-HPC products has been associated with a greater
incidence of chronic GVHD but also improved engraftment
kinetics and leukemia-free survival [33-35]. Themechanisms
underlying the lack of acute GVHD exacerbation are unclear
but may be related to the immunomodulatory effects of G-
CSF on antigen-presenting cells or T cells [36-38]. In vitro, T
cells exposed to G-CSF have decreased proliferative and Th1
cytokine-producing capacity in response to mitogenic
stimulus [39-41]. Whether this alteration of global T cell
responses also affects virus-speciﬁc memory T cells is
unknown.
In the present study, we examined the feasibility of
generating CMV CTL lines directly from G-CSFemobilized
donors and validated a method requiring only 2 to 4 mL of
a typical G-HPC collection (on average, 1%-3% of the total
collection) to reproducibly enrich CMV-speciﬁc T cells
in culture. We compared the expansion kinetics and func-
tionality of these cells and of CTL lines generated from
nonmobilized peripheral blood (NMPB). Seven patients
received CMV-speciﬁc CTL lines expanded from G-HPCTable 1
HPC collection details used for CTL generation
Patient* Collection
Volume, mL
CD34þ Cells,  106/kg Volume
Removed, mL
1 245 2.7 4
2y 204 0.9 4
3 378 3.8 4
4 362 9.2 3
5 311 7.5 4
6 249 6.4 4
7 152 7.7 4
8 289 4.1 3
9 349 8.9 3
Donor 1 191 4.7 1.7
Donor 2 206 6.9 1.5
Mean 266.9 5.7 3.3
SD 76.2 2.7 0.9
TNC indicates total nucleated cells.
* CTLs from G-HPCs from donors 1 and 2 were generated for direct comparison
y Details provided for removal of cells from day 2 collection; a total of 3.1  10products in a prophylactic adoptive immunotherapy phase
I/II clinical trial.METHODS
Participant Details and Eligibility Criteria
Patients who underwent allogeneic HSCT for any hematologic malig-
nancy atWestmead Hospital between October 2006 and July 2011, as well as
their HLA-matched (-A, -B, and -DR loci) or 1 antigen-mismatched related or
unrelated CMV-seropositive donors, were eligible for inclusion in this study.
Participants were recruited from the pool of eligible donorerecipient pairs
based on the availability of donors to provide peripheral blood before
initiation of G-CSF mobilization and/or the laboratory’s capacity for CTL line
generation. CTL lines were generated from donors enrolled in a phase I/II
clinical trial of prophylactic adoptive transfer of donor-derived CMV-speciﬁc
T cells. This study was approved by the Human Research Ethics Committees
of Westmead Hospital, the University of Sydney, and the Australian Bone
MarrowDonor Registry. Informed consent was obtained from all donors and
recipients before enrollment, in accordancewith the Declaration of Helsinki.
The study has been registered on the Australian Clinical Trial Registry
(ACTRN12605000213640 and ACTRN12607000224426).CMV-Speciﬁc T Cell Generation
Tcell products were generated from approximately 100mL of peripheral
blood collected by venesection from donors before G-CSF mobilization or
a proportion of the G-HPC apheresis product. For G-HPC products, absolute
CD34þ cells were enumerated using an in-house single-platform viable
CD34 ﬂow cytometric assay, as described previously [42,43]. If the CD34þ
HPC content exceeded 2.5  106 CD34þcells/kg, a proportion of the collec-
tionwas removed for CTL generation (Table 1). The same method, except for
the starting volume of donor product, was used to generate CMV CTLs from
NMPB or G-HPC products. In brief, samples were diluted in PBS supple-
mented with 0.2% human albumin (Albumex 20; CSL, Parkville, Australia)
and peripheral blood mononuclear cells (PBMCs) isolated by density-
gradient centrifugation using Ficoll-Paque Premium (GE Healthcare, Wau-
kesha, WI). Monocytes were enriched by adherence and differentiated into
dendritic cells (DCs) in CellGro DCmedium (CellGenix, Freiburg im Breisgau,
Germany) supplementedwith 1,000 U/mL GM-CSF and 1,000 U/mL IL-4 for 5
to 6 days. DCs were supplemented with 200 U/mL TNF-a (CellGenix) to
promote maturation and then transfected at a multiplicity of infection of
20:1 with a clinical-grade adenovirus vector (Ad5F35pp65) encoding the
entire CMVpp65 protein (provided by C. Rooney, H. Heslop, and M. Brenner,
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX).
Transfected and irradiated DCs were cocultured with autologous PBMCs in
AIM V medium CTS (Life Technologies, Carlsbad, CA) with 10% heat-
inactivated AB serum (from the Australian Red Cross Blood Service) or
autologous plasma to initiate CMV-speciﬁc T cell expansion. After 7 days,
cultures were restimulated with Ad5F35pp65-transfected DCs and supple-
mented with 20 U/mL IL-2 (Millipore, Billerica, MA, or Miltenyi Biotec,
Bergisch Gladbach, Germany) for 7 days. IL-2 was increased to 50 U/mL for
the ﬁnal week of culture. At the completion of culture, cells were enumer-
ated, washed once, and cryopreserved until use for infusion or quality
assurance testing. Release criteria were>50% postthaw viability,<2% CD14þ
and <2% CD19þ cells, <10% killing of recipient-derived phytohemagglutinin% of Harvest
Removed
TNCs Removed,  109 Reduction in CD34þ
Cells,  106/kg
1.63 1.0 0.04
1.96 0.7 0.02
1.06 1.0 0.04
1.10 0.8 0.10
1.29 1.0 0.10
1.61 0.9 0.10
2.63 0.9 0.20
1.38 0.6 0.06
1.15 0.8 0.10
2.09 0.4 0.10
1.94 0.5 0.13
1.62 0.8 0.09
0.49 0.2 0.05
with CTLs derived from NMPB.
6 CD34þ cells/kg were infused for transplantation.
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and negativity for mycoplasma by PCR.Assessment of CMV CTL Lines
CTL lines were phenotyped by ﬂow cytometry using monoclonal anti-
bodies directed against CD3, CD4, CD8, CD56, CD14, CD19, CD45RA, CD45RO,
CD62L, and HLA-DR (BD Biosciences, San Jose, CA). Enumeration and
viability were assessed by trypan blue exclusion. Where applicable, the
proportion of T cells with speciﬁcity toward the HLA-A2erestricted
CMV epitope NLVPMVATV and HLA-B7erestricted epitope TPRVTGGGAM
was determined by staining with PE-conjugated MHC tetramers (Beckman
Coulter, Brea, CA). Cells were acquired and analyzed with a Cyan ADP
(Beckman Coulter) or FACScanto 2 (BD Biosciences) ﬂow cytometer.
The cytotoxic speciﬁcity and potential for alloreactivity of CMV-CTL lines
was assessed using a standard 4-hour 51Cr-release assay. Alloreactivity was
tested by coincubation of CMV CTL lines with PHA blasts derived from
pretransplantation recipient blood. CMV-speciﬁcity was tested using
recipient PHA blasts preincubated with an overlapping peptide mix of CMV
pp65 (15mer overlapping by 11 aa; JPT Peptide Technologies, Berlin,
Germany) as target cells.T Cell Infusion and Eligibility Criteria for Treatment
Patients undergoing allogeneic HSCT for any hematologic malignancy at
Westmead Hospital from HLA-matched (at HLA-A, -B, and -DR loci) or
1 antigen-mismatched related or unrelated donor were eligible to receive
a single infusion of donor-derived CMV-speciﬁc Tcells. Patients were treated
with institutional transplantation protocols at the discretion of the treating
physicians. There was no mandated conditioning or immunosuppressive
regimen. Patients were eligible to receive a single prophylactic infusion of
2  107/m2 donor-derived CMV-speciﬁc T cells at 28 days after HSCT or later
if the following additional treatment eligibility criteria were met: no
evidence of grade II or greater acute GVHD, no use of steroids at a dose
equivalent to or greater than prednisone or methylprednisone >1 mg/kg
administered within 72 hours before cell infusion, no use of any broad-
spectrum lymphocyte antibody (eg, antithymocyte globulin, anti-
lymphocyte globulin, Campath) within 4 weeks of CTL infusion or planned
within the 4 weeks after infusion, no abnormal liver function (aspartate
aminotransferase or alanine aminotransferase <3 times normal, total bili-
rubin <2 times normal) or renal function (creatinine <2 times normal),
and estimated life expectancy of at least 6 months. Cells were thawed
rapidly and transferred to a syringe for immediate infusion. The primary
endpoints were safety of infusion and CMV reactivation. Secondary
endpoints were incidence of GVHD, use of antiviral agents, and CMV-speciﬁc
immune reconstitution.Patient Monitoring
Clinical management was according to institutional protocol. Clinical
review and blood collection for immune monitoring were performed for
up to 12 months after infusion, with clinical follow-up by chart review
thereafter. Monitoring for CMV reactivation was performed using peri-
pheral blood CMV PCR at weekly intervals for the ﬁrst 100 days post-
transplantation and then monthly until weaning of immunosuppressive
medications. Ganciclovir 5 mg/kg twice daily was started when 2 consec-
utive CMV PCR results showed increasing copy numbers or a single result
exceeded 2,000 copies/mL. Foscarnet 60 mg/kg 3 times daily was used if
ganciclovir was contraindicated. Clinical adverse events were graded
according to the National Cancer Institute’s Common Toxicity Criteria
version 2.0.
Monitoring of CMV-directed immunity was performed on the day
of infusion (preinfusion and 2 hours postinfusion), weekly for 4 weeks
after infusion, and every 3 months thereafter for up to 12 months. Analysis
of postinfusion CMV immunity was performed on cryopreserved PBMCs
obtained by density-gradient centrifugation and batched to avoid interassay
variability. Reconstitution of T cell immunity to whole CMV pp65 was
assessed by IFN-g enzyme-linked immunospot assay. For this, 0.5-1  105
PBMCs from each time point were suspended in 200 mL of AIM V/10% human
AB serum and stimulatedwith CMV pp65 protein overlapping peptidemixes
(JPT Peptide Technologies) for 18 hours in multiscreen, 96-well ﬁlter plates
(MAIPS4510; Millipore) coated with capture antibody (51-2555KZ;
BD Biosciences). After washing and incubation with detection antibody (51-
1890KZ; BD Biosciences), spots were developed using ExtrAvidin and Sig-
maFast BCIP/NBT alkaline phosphatase substrate (Sigma-Aldrich, St Louis,
MO) according to the manufacturer’s directions. Plates were analyzed using
the AID Elispot Reader, and spots were counted using iSpot version 6.0 (both
from Autoimmune Diagnostika, Strassberg, Germany). Results are expressed
as spot-forming cells per 105 cells. Tests were performed in duplicate for
each time point.Intracellular Cytokine Flow Cytometry
Between 0.5 and 1  106 T cells were coincubated with an overlapping
peptide mix of CMV pp65 (JPT Peptide Technologies) for 4 hours in the
presence of anti-CD28 and CD49d antibodies (BD Biosciences). Monensin
(2 mM) and brefeldin A (1 mg/mL) were added for the last 4 hours, followed
by labeling with ﬂuorochrome-conjugated antibodies to cell surface anti-
gens CD3, CD4, and CD8. Intracellular labeling for IFN-g (B27) and IL-2
(MG1-17H12) was performed using the Cytoﬁx/Cytoperm Kit (BD Biosci-
ences) according to the manufacturer’s instructions. Maximum cytokine
responses were determined by activating T cells with 5 ng/mL phorbol 12-
myristate 13-acetate and 1 ng/mL ionomycin (Sigma-Aldrich). Baseline
cytokine levels were measured with T cells without antigen reexposure.
Samples were acquired and analyzed with a Cyan ADP (Beckman Coulter) or
FACScanto 2 (BD Biosciences) ﬂow cytometer.RESULTS
Expansion and Phenotype of CMV-Speciﬁc CTLs Generated
from G-HPC Products and NMPB
A total of 63 T cell products were generated from alloge-
neic HSCT donors, and 11 used an aliquot of cells removed
from the G-HPC product. Between 1.5 and 4 mL of the
product (0.4-1  109 total nucleated cells) was removed,
corresponding to 1.1% to 2.6% of the total collection (Table 1).
The reduction in infused CD34þ cell dose as a result of cell
removal for CTL generation ranged from 0.02 to 0.2  106
CD34þ cells/kg (Table 1). After 21 days in culture, total cell
number increased by a mean of 19.3-fold (range, 9.2-fold
to 36.3-fold) (Figure 1A). The ﬁnal product consisted
primarily of T cells (mean, 97.3%  1.9%) of memory pheno-
type (mean, 97.2%  2% CD45ROþ) with variable expression
of CD62L (median, 11.7%; range, 2% to 29.8%). There were few
contaminating natural killer (NK) cells (mean, 1.8%  1.8%),
monocytes (0.1%  0.1%), or B cells (0.4%  0.4%) (Figure 1B).
Eight of 11 products contained a higher percentage of
CD8 T cells (median, 63.8%; range, 9.4% to 93.8%) compared
with CD4 T cells (median, 26.6%; range, 4.9% to 71.1%)
(Figure 1B). Enrichment of T cells recognizing immunodo-
minant HLA-A2e and/or HLA-B7erestricted CMV epitopes
(NLV and TPR) could be assessed by MHC tetramer staining
for 7 donors. CMV tetramer-positive CD8 T cells accounted
for up to 75% of all cells (median, 37.8%; range, 7.4% to 75%)
(Figure 1B).
We compared the T cell products generated from G-HPC
products with CTL lines generated previously at our center
from blood collected by venesection beforemobilization. The
composition of PBMCs isolated fromG-HPC products differed
from NMPB with fewer T cells (mean, 45.4%  11.4% versus
59.7%  10.4%; P ¼ .001) and NK cells (mean, 3.3%  1.4%
versus 8.1%  3.3%; P ¼ .0006) but had a higher percentage
of monocytes (mean, 26.3%  10.3% versus 11.8%  6.5%;
P ¼ .0001) (Figure 1C). The proportion of CD4þ and CD8þ
T cells, and memory (CD45RO) and naïve (CD45RA) pop-
ulations, did not differ signiﬁcantly between the 2 sources
(Figure 1C). There was no difference in mean fold increase
in total cell number at day 21 of culture between 52 NMPB-
derived CTL lines and G-HPCederived CTL lines (14.9  10.3
versus 19.3  8.6; P ¼ .16) (Figure 1D). The phenotype of
CMV CTL lines derived from NMPB closely resembled
G-HPCederived CTLs (Figure 1E), being predominately T cells
(mean, 88.7%  18.2%) of memory phenotype, with the
majority of nonmobilized blood products (26 of 33 assessed)
containing more CD8 T cells (median, 63.1%; range, 23% to
91%) than CD4 T cells (median, 24.4%; range, 2.5% to 59%).
None of these characteristics showed statistically signiﬁcant
differences between NMPB-derived CTLs and G-HPCe
derived CTLs (P > .05 for all comparisons). However, there
was a signiﬁcantly higher percentage of T cells (97.3% versus
Figure 1. Expansion and phenotype of CMV-speciﬁc T cell cultures from G-HPC apheresis products. (A) Fold increase in total cell number after 14 days and 21 days in
culture for G-HPCederived products (n ¼ 9). (B) Phenotype of cells expanded from G-HPC products at the completion of culture (n ¼ 11). Dots represent individual
cultures, and horizontal lines indicate means. (C) Phenotypic comparison of PBMC composition isolated from NMPB (dark gray; n ¼ 15) and G-HPCs (light gray; n ¼
16). *P .05. (D) Comparison of expansion kinetics of CMV CTLs expanded from NMPD (dark gray; n ¼ 52) or G-HPC (light gray; n ¼ 11) collections. (E) Comparison of
cell phenotype of cultures expanded from NMPD (dark gray; n ¼ 33) or G-HPC products (light gray; n ¼ 11); bars represent means. *P  .05.
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.013) in cultures expanded from G-HPC products compared
with those from NMPB (Figure 1E).
Comparison of CMV CTLs Expanded from NMPB and
G-HPC Products from the Same Donor
Two donors provided blood before G-CSF mobilization
and also consented to the use of their mobilized HPCs
collected for CTL generation. This enabled a direct compar-
ison of cell expansion, phenotype, and function with paired
samples from the same donor. In both cases, expansion was
greater when generated from the G-HPC products than from
NMPB (fold increase, 17.1 and 16.4 versus 7.9 and 6.6)
(Figure 2A). There were minor differences in cell phenotype
based on the starting product (Figure 2B). Comparedwith the
NMPB-derived culture, the G-HPC culture from donor 1 had
higher percentages of T cells (94% versus 76.7%) and CD8
T cells (83.7% versus 53.5%) and lower percentages of CD4
T cells (9.4% versus 16.9%) and NK cells (5.5% versus 19.4%). In
contrast, the G-HPCederived culture from donor 2 had
a higher CD4 T cell content (26.6% versus 15.2%) and a corre-
spondingly lower percentage of CD8 T cells (68% versus 81%).The proportion of T cells for donor 1 recognizing the HLA-
A*0201erestricted NLV epitope increased from 0.28% to 23%
of all T cells when expanded from NMPB and from 0.33% to
42% of all T cells when expanded from G-HPC products. The
baseline percentage of T cells for donor 2 recognizing the NLV
epitope or HLA-B*0702erestricted epitope TPR was not
determined. However, at the completion of culture, 30.8% and
34.8% of all Tcells derived fromNMPB recognized theNLV and
TPR epitopes, respectively, comparedwith 16.6% and 24.6% of
Tcells derived fromG-HPC products. CTL lines expanded from
both cell sources exhibited cytotoxicity against HLA-matched
target cells presenting CMV antigens (Figure 2C) and
produced IFN-g and IL-2 on reexposure to CMVantigens (data
not shown).
Cytotoxicity, Alloreactivity, and Cytokine Production
by CMV T Cell Products
Eight of the G-HPCederived T cell products were assessed
for alloreactive potential by coincubation of donor-derived
T cell lines with 51Cr-labeled PHA blasts generated from
recipients pretransplantation. All exhibited no alloreactivity
with speciﬁc lysis of 0% at an effector cell (ie, CTL)-to-target
Peripheral 
blood
G- HPC
Peripheral 
blood
G- HPC
Figure 2. Direct comparison of CMV CTLs expanded from G-HPCs and NMPB from the same donor. (A) Fold increase in total cell number after 21 days in culture when
derived from NMPB (black) or G-HPC products (gray) for 2 donors. (B) Comparison of phenotype of cultures expanded from NMPB (dark gray) or G-HPC products (light
gray) for 2 donors. (C) Representative cytotoxicity assay (donor 1) of CMV T cell cultures from NMPB (left) and HPCs (right) against HLA-matched target cells pulsed
with an overlapping peptide mix of the CMV pp65 protein (A), NLV peptide (B), or no antigen control (:).
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cytotoxic activity, target cells were pulsed with overlapping
peptides covering the entire CMV pp65 protein. Eight of
9 T cell lines tested that were generated from G-HPC prod-
ucts exhibited high CMV-speciﬁc cytotoxicity (median,
55.3%; range, 1.7% to 94.6% speciﬁc lysis at an E:T of 20:1)
(Figure 3). The CTL line without demonstrable cytotoxicity
consisted predominately of CD4þ T cells (77.4%), with few
cytotoxic CD8þ T cells (9.4%). Similarly, no signiﬁcant allor-
eactivity was observed in 33 CTL lines generated from NMPB
(median, 1%; range, 0% to 5.3% speciﬁc lysis at an E:T of 20:1)Figure 3. Cytotoxic capacity and alloreactivity of CMV-speciﬁc CTL cultures
using the Cr51 assay. Potential alloreactivity was measured by speciﬁc lysis of
pretransplantation recipient-derived target cells coincubated with CTL lines
expanded from NMPB (n ¼ 33) or G-HPC products (n ¼ 9) at a CTL:target cell
ratio of 20:1. CMV-speciﬁc cytotoxicity was measured by speciﬁc lysis (E:T 20:1)
of target cells loaded with an overlapping peptide mix covering CMV pp65.(Figure 3), and CMV-speciﬁc cytotoxic activity was detected
in 32 of 33 CTL lines generated from NMPB (median, 56.5%;
range, 2.6%-100% speciﬁc lysis at an E:T of 20:1) (Figure 3).
The sole CTL line without cytotoxicity had an unusually high
NK cell content (60%), with CD8þ T cells composing only
14.9% of the ﬁnal product. There was no difference in CMV-
directed cytotoxicity (mean cytotoxicity, 55.3% versus 56.5%
at an E:T of 20:1; P ¼ .53) by CTL lines expanded from G-HPC
products compared with those derived from NMPB.
The speciﬁcity of T cell cultures to CMV was also assessed
by measuring the production of inﬂammatory cytokines
IFN-g and IL-2 after reexposure to the CMV pp65 antigen
(Figure 4A). Four cultures generated from G-HPCs were
examined. The percentage of CD3þ cells that produced IFN-g
after restimulation with pp65 ranged from 15.7% to 62%
(median, 40.7%) (Figure 4B). A smaller percentage of cells
produced IL-2 (median, 2.9%; range, 1.8% to 3.9%). The
majority of cytokine-producing cells were of the CD8þ T cell
subset (Figure 4B). The proportion of IFN-geproducing CMV-
speciﬁc T cells was similar in 6 products generated from
NMPB (median, 43.2%; range, 14.7% to 80.1%) (Figure 4C). On
average, a higher proportion of T cells derived from NMPB
produced IL-2 in response to pp65 compared with those
derived from G-HPC products, but the difference was not
statistically signiﬁcant (mean, 9.5% versus 2.9%; P ¼ .25).
Infusion of CMV-Speciﬁc T Cells
A total of 9 HSCT recipients had CMV CTL products
generated from G-HPCs collected for infusion; however,
2 patients were excluded from analysis owing to the devel-
opment of GVHD. Seven patients received infusions of CMV
CTL lines expanded from G-HPCs collected between
September 2010 and August 2011. Patient characteristics are
seen in Table 2. The median agewas 53 years (range, 42 to 68
Figure 4. Cytokine production by CD3, CD4, and CD8 T cells in response to restimulation with CMV pp65. (A) Representative dot plots (donor 2, G-HPCederived
culture) gating on CD3þ T cells to measure IFN-g and IL-2 production in the absence of antigen (top row, negative control) and after restimulation with CMV pp65
(bottom row). (B) Production of IFN-g and IL-2 by CD3þ, CD8þ, and CD4þ T cells on restimulation with an overlapping peptide mix covering CMV pp65 for cultures
expanded from G-HPCs (n ¼ 4). Each line represents the cytokine response from a different culture and shows the change in the percentage of cytokine-expressing
cells in the presence (pp65) and absence (neg) of antigen. (C) Comparison of cytokine responses in individual CMV T cell cultures expanded from G-HPC products (C)
and NMPB (:) producing IFN-g and IL-2 in response to CMV pp65. Horizontal lines indicate means.
L.E. Clancy et al. / Biol Blood Marrow Transplant 19 (2013) 725e734730years). Two patients received myeloablative conditioning
with cyclophosphamide 60 mg/kg/day for 2 days and i.v.
busulfan 3.2 mg/kg/day for 4 days, and the other 5 patients
received reduced-intensity conditioning with ﬂudarabine
30 mg/kg/day for 5 days, melphalan 140 mg/m2 in a single
dose, carmustine 200mg/m2/day for 2 days, and in vivo T cell
depletionwith rabbit antithymocyte globulin (ATG-Fresenius
S, Fresenius Biotech GmBH, Gräfelﬁng, Germany) 10mg/kg in
a single dose. The 2 patients age >55 years had a 25% dosage
reduction of melphalan and carmustine. All patients had
a fully HLA-matched donor, 6 with a sibling donor and 1 with
an unrelated donor. Five patients were CMV seropositive, and
2 were CMV-seronegative. Five patients underwent HSCT for
acute myelogenous leukemia, 4 of whom were in ﬁrst
remission. The remaining 2 patients underwent HSCT for
myelodysplastic syndrome and myelodysplastic myelopro-
liferative syndrome.
Patients were eligible to receive a CMV CTL infusion from
day 28 post-HSCT. However, the median day of infusion was
45 days post-HSCT (range, 38 to 90 days). Six patients
received cells between days þ38 and þ52, and 1 patient
(patient 6) had a prolonged delay until day þ90 owing to
grade II acute GVHD of the gastrointestinal tract, which had
resolved at the time of infusion. In the 6 patients treated
between days þ38 and þ52, the primary reasons for delay
were completion of quality assurance tests to satisfy cell
product release criteria and outpatient appointment timing
(n ¼ 5). One patient was delayed because of previous CMV
reactivation. Five patients received the target cell dose of 2 107 cells/m2; patient 4 received a reduced dose of 1.1  107
cells/m2, and patient 5 received a reduced dose of 1.2  107
cells/m2, owing to lower ex vivo expansion. Despite not
reaching the target cell dose, the CTL product for patient 4
exhibited high cytotoxic activity against target cells pre-
senting CMV antigens (51.6% speciﬁc killing at an E:T ratio of
20:1) and was enriched for T cells recognizing the CMV pp65
HLA-A*0201erestricted epitope NLVPVATMV, which
accounted for 37.7% of cells in the ﬁnal product. The CTL
product for patient 5 consisted predominately of CD4þ T cells
(71.1%), with few cytotoxic CD8þ T cells (9.4%) and exhibited
low but detectable cytotoxicity against CMV pp65-loaded
target cells (4.2% speciﬁc killing at an E:T ratio of 40:1).
There were no immediate adverse events associated with
infusion. Median length of follow-up was 17 months post-
HSCT (range, 4 to 21 months).
Three patients experienced an episode of CMV reac-
tivation before infusion with CMV-speciﬁc T cell lines (on
days þ31, þ38 and þ45 post-HSCT). Patient 7 was PCR
positive (quantitation below detectable level) in the 2 weeks
before infusion but negative at the time of CTL infusion and
remained so for the duration of follow-up. Patient 4 had
a plasma CMV viral load of 3,860 copies/mL at the time of
infusion and was treated with valaciclovir 2 g 4 times daily
for 2 weeks at the discretion of the treating physician,
starting 3 days before CTL infusion. At 1 week postinfusion,
the CMV viral load had dropped to below 600 copies/mL,
and within 2 weeks, it was negative. At day 59 postinfusion,
the patient experienced an additional episode of low-level
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L.E. Clancy et al. / Biol Blood Marrow Transplant 19 (2013) 725e734 731CMV reactivation (<600 copies/mL), which resolved without
intervention. There were no cases of de novo CMV reac-
tivation in the remaining 4 patients, who had no CMV reac-
tivation before cell infusion. None of the 7 patients required
treatment with i.v. ganciclovir or foscarnet. There were no
cases of CMV disease.
Patient 6 had grade II acute GVHD of the gastrointestinal
tract before cell infusion. GVHD was not exacerbated after
cell infusion. Patient 5 developed grade II acute GVHD of
the gastrointestinal tract at 7 days after CTL infusion, which
was successfully treated with corticosteroids. Patients 2 and
4 developed chronic GVHD, which was treated successfully
with corticosteroids. Patient 3 was diagnosed with adeno-
carcinoma of the lung and died from respiratory failure
4 months post-HSCT. The adenocarcinomawas likely present
at the time of HSCT but was not detected on the pre-
transplantation workup. Patient 4 developed a spontaneous
intracerebral hemorrhage at 8 months post-HSCT, which
resolved with conservative management, as well as herpes
zoster with postherpetic neuralgia at 9 months post-HSCT.
No patient experienced relapse during the follow-up period.
Monitoring CMV Immunity after CTL Infusion
Patients were monitored before and after infusion
for immune function directed toward CMV pp65 antigen by
IFN-g enzyme-linked immunospot assay. Six of the 7 patients
participated in this aspect of the study. The results of
immune monitoring are shown in Figure 5. Detectable pp65
reactivity was noted in 5 of the 6 patients and in all patients
in whom CMV reactivation occurred. The level of CMV-
speciﬁc immunity appeared to diminish in the context of
prednisone use in patients 2 and 4 and was low throughout
the period of prednisone use in patient 6.
DISCUSSION
There is increasing clinical evidence that the adoptive
transfer of pathogen-speciﬁc T cells can safely prevent
and treat a broad range of opportunistic infections in
immune-compromised patients after HSCT. This therapy
is currently available in only a small number of centers
worldwide, however. The feasibility of implementing adop-
tive immunotherapy would be improved if cell generation
and administration could be integrated into established
quality control systems of blood and marrow transplantation
centers and laboratories. In this article, we have described
the generation of clinical-grade CMV-speciﬁc CTLs directly
from G-HPCs collected by leukapheresis for transplantation.
This procedure required <1  109 total nucleated cells,
equating to the removal of 4 mL of blood product from
apheresis collections. The reduction in CD34þ progenitor
cells available for transplantation as a result of cell removal
for CTL generation ranged from 0.02 to 0.2 106 CD34þ cells/
kg, which is unlikely to signiﬁcantly affect engraftment
except in rare cases with limited stem cell numbers. The
minimum CD34þ cell dose in the G-HPC harvest required for
entry into the present study was 2.5  106 cells/kg, to reduce
the risks associated with low cell numbers. In this study,
in no case was the CD34þ cell dose in the stem cell harvest
a limiting factor to study enrollment, and all patients
engrafted adequately. Furthermore, we analyzed 384 aphe-
resis collections processed by our laboratory since 2006 and
found that 91% exceeded the minimum dose for entry into
the present study.
Seven patients received an infusion of CMV-speciﬁc CTLs
generated from G-HPC collections. Five received the target
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Figure 5. Measurement of immune function in 6 patients over time. Virus-speciﬁc immunity measured by enzyme-linked immunospot assay (reported as spot-
forming units/105 cells; pp65, blue; adenovirus, black) and quantitative CMV PCR (copies/mL; red).
L.E. Clancy et al. / Biol Blood Marrow Transplant 19 (2013) 725e734732cell dose of 2  107cells /m2, and 2 received a reduced dose
owing to the number of cells available at the completion
of ex vivo expansion. Both cultures that did not reach the
target cell dose exhibited demonstrable cytotoxic activity
against target cells presenting CMV antigens, and there was
no evidence of reduced efﬁcacy in these 2 patients. Our
protocol used monocyte-derived DCs transfected with an
adenovirus vector encoding the whole CMV pp65 protein
(Ad5F35pp65), to activate and promote the proliferation of
antigen-speciﬁc T cells. This resulted in the enrichment
of predominatelymemory T cells, with a mix of both CD8 and
CD4 subsets. In 6 donors, we saw the expected enrichment
of cytotoxic T cells recognizing immunodominant HLA-A2e
and/or HLA-B7erestricted CMV epitopes (NLV and TPR),
accounting for up to 75% of T cells in the ﬁnal product.
CMV CTLs expanded from G-HPCs efﬁciently lysed target
cells loaded with CMV pp65 peptides and produced IFN-g
on restimulation.Reluctance to use G-HPCs as the cell source for CTL
expansion in adoptive immunotherapy trials stems from
studies that attempted to explain the unexpectedly low
rate of acute GVHD in early clinical trials of peripheral blood
stem cell transplantation. G-CSF priming promotes Th2 or
regulatory T cell polarization, acts directly on T cells
to decrease proliferation and Th1 type cytokine production,
and results in an increased frequency of tolerizing DCs
and suppressivemonocytes in the HPC collection [36-41].We
did not directly assess the phenotype or function of
monocyte-derived DCs, but previous studies have shown
that monocytes from G-CSFemobilized collections can be
differentiated into potent antigen-presenting cells express-
ing high levels of costimulatory molecules that produce
equivalent quantities of IL-12 compared with DCs derived
from NMPB [44-46].
Whether the perturbation of global T cell responses after
G-CSF mobilization also pertains to virus-speciﬁc Th1
L.E. Clancy et al. / Biol Blood Marrow Transplant 19 (2013) 725e734 733memory T cells is unknown. We found no evidence of
impaired expansion of CMV-speciﬁc T cells derived from
G-CSFemobilized stem cell harvest products. Comparison of
CMV CTLs generated from primed apheresis products with
52 CMV CTL lines previously generated from NMPB at our
center revealed similar expansion kinetics and phenotype
at the completion of culture. There was no signiﬁcant
difference in CMV-directed cytotoxicity or in the proportion
of T cells that produced IFN-g after reexposure to CMV pp65.
We have assessed an additional 13 G-HPCederived CTL lines
generated for other clinical studies at our center and
observed the production of IFN-g in all cultures (data not
shown). Taken together, these results suggest that previous
treatment of donors with G-CSF 10 mg/kg/day for 5 days to
promote HPC mobilization does not impede the ex vivo
expansion of memory T cells, and that these cells retain the
capacity to perform effector functions associated with
protective immunity.
Adoptive transfer of donor-derived allogeneic T cells
carries the risk of inducing GVHD. We performed allor-
eactivity testing on CMV CTL lines before infusion by
coincubating CTL lines with HSCT recipientederived target
cells and measured cytotoxicity by chromium release assay.
We found no in vitro evidence of alloreactivity in any of the
CTL lines expanded from G-HPC products or from NMPB,
although cytokine production may be a more sensitive me-
asure of alloreactive potential, as reported recently [47,48].
Of the 7 patients who received infusions of CMV CTL lines
expanded from G-HPC products, 1 developed grade II acute
GVHD of the gastrointestinal tract at 7 days after CTL infu-
sion, and 2 developed chronic GVHD, all of whom responded
to treatment with corticosteroids.
Deﬁnitively excluding CTL infusion as a contributing
factor to the onset of GVHD is difﬁcult, considering that
treatment was provided during a period when GVHD and
other transplantation-related complications are common.
However, we recently analyzed data from 50 patients infused
with CMV-speciﬁc T cells after allogeneic HSCT at our center,
and found no difference in rates of acute or chronic GVHD
compared with contemporaneously treated controls (data
not shown). Moreover, no increase in de novo GVHD was
found in 153 recipients of virus-speciﬁc T cell infusions,
including 73 with an HLA-mismatched donor [48]. Several
groups have reported favorable outcomes in early-phase
clinical trials involving the infusion of donor-derived CMV-
speciﬁc CTLs post-HSCT [17-27], although direct comparison
is complicated by differences in manufacturing, dosage, and
timing of infusion. On balance, these studies support the
notion that infusion of CMV CTLs is not associated with
an increased risk of GVHD, although a deﬁnitive large-cohort
comparison study has yet to be reported. None of the
7 patients treated in the present study required treatment
with i.v. ganiclovir or foscarnet, although 1 patient with CMV
reactivation at the time of CTL infusion was concurrently
treated with valaciclovir. In this patient, the CMV viral load
became undetectable within 2 weeks, although clearly,
we cannot draw any ﬁrm conclusions regarding the contri-
butions of antiviral therapy or T cells in controlling CMV
reactivation and disease in this case. There were no episodes
of late CMV reactivation (after day þ100) and no cases of
CMV disease.
This study demonstrates the feasibility of generating
CMV-speciﬁc CTLs directly from G-CSFemobilized HPCs
for prophylactic adoptive transfer. As new technologies
evolve, improvement in transplantation outcomes likely willinvolve manipulation of a single HPC collection to provide
not only hemopoietic recovery but also assisted immune
reconstitution and targeted antileukemic activity. There are
several advantages to using the apheresis product as the
source of starting material. Doing so provides access to
a greater number of cells for processing and avoids the
unnecessary duplication of donor assessment, infectious
disease testing, product collection, and subsequent product
transport to processing facilities by using the existing systems
of accredited transplantation centers. With the use of G-HPC
products, adoptive immunotherapy is available to patients
with unrelated donors collected at external facilities,
including those located overseas, from whom transport of
an additional blood sample is often not practical. We believe
that use of the HPC collection will facilitate the more rapid
incorporation of T cell therapies into routine clinical care.ACKNOWLEDGMENTS
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